PAN-PI3K/MTOR INHIBITOR SF1126
Cancer
Semafore PharmaceuticalsSmall moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 65/ 100
Competitive context
1412 Active assets in the Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | BB |
Vitamin B6 M.D. Anderson Cancer Center | Phase 4 | BB |
PROPOFOL Hong Kong Children's Hospital | Phase 4 | BB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PAN-PI3K/MTOR INHIBITOR SF1126 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →